Premium
Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on
Author(s) -
Samlowski Wolfram E.,
Wong Bryan,
Vogelzang Nicholas J.
Publication year - 2008
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2008.07670.x
Subject(s) - sunitinib , temsirolimus , sorafenib , medicine , bevacizumab , tyrosine kinase inhibitor , cancer , oncology , kidney cancer , pharmacology , intensive care medicine , discovery and development of mtor inhibitors , pi3k/akt/mtor pathway , chemotherapy , apoptosis , biochemistry , chemistry , hepatocellular carcinoma
In the last 3 years there has been a dramatic increase in the treatment options for patients with metastatic renal cancer. In addition to the cytokines interferon and interleukin 2, recently approved agents include sorafenib, sunitinib, temsirolimus and bevacizumab. A plethora of agents that are likely to have clinical activity are currently in the development ‘pipeline’. This brief review is intended to overview recent developments, and to identify advances that are likely to influence treatment decisions.